Review of Tumor Necrosis Factor Inhibitors on Rheumatoid Arthritis.
- Author:
Jung Soo SONG
1
Author Information
- Publication Type:Review
- Keywords: Rheumatoid arthritis; Treatment; Tumor necrosis factor inhibitors; Biologic agents
- MeSH: Arthritis, Rheumatoid*; Biological Factors; Joints; Korea; Molecular Biology; Tumor Necrosis Factor-alpha*; Adalimumab; Infliximab; Etanercept
- From:The Journal of the Korean Rheumatism Association 2007;14(1):1-14
- CountryRepublic of Korea
- Language:Korean
- Abstract: Advanced knowledges of cellular and molecular biology led to the development of therapies of rheumatoid arthritis (RA). The introduction of biologic agents into clinical practice has had a profound effect on the current management of RA. These agents can rapidly enhance functional status and inhibit the progression of joint damage from the disease. Tumor necrosis factor (TNF) inhibitors are the representative biologic agents for the treatment of RA. Their clinical efficacy and safety were revealed through many clinical trails. Novel TNF inhibitors and other biologic agents for the treatment of RA are developing continuously. Promising biologic agents such as TNF inhibitors have become an important part of treatment armamentarium for RA, although they have some side effects and problems to be solved. These agents may contribute to achieve the sustained remission and eventually cure of RA. Currently available TNF inhibitors in Korea include etanercept, infliximab and adalimumab. This review article introduces past, present, and future of the TNF inhibitors and suggests guidelines for the proper use of them on RA.
